Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Abstract

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.

Modulatory effects of curcumin on heat shock proteins in cancer: A promising therapeutic approach

“…24 Curcumin affects many signaling pathways that lead to multiple health benefits. 28 It has been shown to be of benefit in inflammatory conditions [29][30][31][32][33] for the treatment of kidney 34 and liver [35][36][37][38] disorders, metabolic syndromes, 39 diabetes, 40 atherosclerosis, 41,42 dyslipidemia, [43][44][45][46] anxiety and/or depression, 47,48 viral diseases, 49 drug toxicity, 50 musculoskeletal, 51,52 and ischemic injury, 53 as well as having antitumor 49,[54][55][56] and antioxidant actions. 57 Furthermore, curcumin has shown efficacy in the management of degenerative eye conditions.…”

The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors

“…From decades ago, hypercholesterolemia has been recognized as an important and modifiable risk factor for cardiovascular diseases (CVDs) 1,2 . Several qualified meta-analyses have documented that cholesterol reduction with statins decreases CV morbidity and mortality in people with different baseline CV risk 3–5 ; therefore, most guidelines recommend lipid-lowering therapy to prevent CVD.…”

Hormetic effects of curcumin: What is the evidence?

“…, epigenetic mechanisms (Momtazi, Derosa, Maffioli, Banach, & Sahebkar, 2016;Soflaei et al, 2018), coagulation and hemostasis (Keihanian, Saeidinia, Bagheri, Johnston, & Sahebkar, 2018;Tabeshpour, Hashemzaei, & Sahebkar, 2018), lipid metabolism and lipoprotein function (Cicero et al, 2017;Ganjali et al, 2017;Panahi, Khalili, Hosseini, Abbasinazari, & Sahebkar, 2014;Sahebkar, 2014), hepatic fat accumulation (Zabihi, Pirro, Johnston, & Sahebkar, 2017), and carcinogenesis (Hamzehzadeh, Atkin, Majeed, Butler, & Sahebkar, 2018;Mirzaei et al, 2016;Teymouri, Pirro, Johnston, & Sahebkar, 2017). In particular, there is evidence from clinical trials suggesting the safety and efficacy of curcumin and curcuminoids in several diseases such as osteoarthritis (Panahi, Rahimnia, et al, 2014;Sahebkar & Henrotin, 2016), anxiety and depression (Panahi, Badeli, Karami, & Sahebkar, 2015), type 2 diabetes (Panahi et al, 2018), respiratory diseases (Lelli, Sahebkar, Johnston, & Pedone, 2017), metabolic syndrome (Panahi, Khalili, et al, 2014), nonalcoholic fatty liver disease (Panahi, Kianpour, et al, 2016;Panahi et al, 2017;Rahmani et al, 2016), ulcerative colitis (Masoodi et al, 2018),and chronic obstructive pulmonary disease (Panahi, Ghanei, Bashiri, Hajihashemi, & Sahebkar, 2014).…”